Cyclooxygenase-2 and epidermal growth factor receptor expressions in different histological subtypes of cervical carcinomas

• Type: Article in International Scientific Journal
• Date: 2007

Authors

Baltazar, F (Author) Other; Longatto Filho, A (Author) Other; Pinheiro, C (Author) Other; Moreira, MAR (Author) Other; Silva Queiroz, GS (Author) Other; Bittar Oton, GJB (Author) Other; Fraga Junior, A (Author) Other; Jube Ribeiro, LFJ (Author) Other; Fernando Schmitt (Author) FMUP

Journal

Title: International Journal of Gynecological Pathology

Vol. 26

Pages: 235-241

ISSN: 0277-1691

Publisher: Wolters Kluwer Health

Indexing

ISI Web of Knowledge - 24 Citations

Scopus - 26 Citations

Other information

Authenticus ID: P-004-93N

DOI: 10.1097/pgp.0b013e31802f1996

Abstract (EN): This study was designed to evaluate the significance of cyclooxygenase (COX)-2 and epidermal growth factor receptor (EGFR) expression in a series of cervical adenocarcinoma (AC), cervical adenosquamous carcinoma (ASC), and cervical squamous cell carcinoma (SCC). One hundred thirty cases of cervical carcinoma (30 ASC, 50 AC, and 50 SCC) were analyzed for COX-2 and EGFR expressions using specific primary antibodies. Samples were scored semiquantitatively as follows: (-), 0% of unnumoreactive cells; < 5% of immunoreactive cells: (++), 5% to 50% of immunoreactive cells; and (+++), > 50% of immunoreactive cells. The COX-2 expression was more frequently positive than EGFR in all cervical cancers studied. The COX-2 expression was also more prominent in AC than in ASC (P = 0.003). Expression of either COX-2 or EGFR was significantly different when comparing SCC with AC (P < 0.001 and P = 0.04, respectively). There was no significant correlation between COX-2 and EGFR expressions and age at diagnosis, recurrence, distant metastasis, and/or positive status of regional lymph nodes, neither between COX-2 and EGFR coexpression and the clinical data analyzed. Nevertheless, our data support that there are significant differences between EGFR and COX-2 expressions in the 3 different histogenetic types of cervical cancer. Also, in terms of therapeutic strategies, our data can be valuable in the selection of patients eligible to receive specific EGFR/COX-2-targeted therapy.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 7